

**CARDIAC REMODELLING IN  
HYPERTROPHIC CARDIOMYOPATHY AND  
DIABESITY**

Wei Wen Lim

BSc. (Hons)

Centre for Heart Rhythm Disorders

The School of Medicine

The University of Adelaide

A thesis submitted to the University of Adelaide in fulfilment  
of the requirements for the degree of

DOCTOR OF PHILOSOPHY

DECEMBER 2015

*To my parents, Yong Meng and Florence,  
my sister, Shu Ping,  
and my partner, Melissa*

# Table of Contents

<b>ABSTRACT</b> .....	<b>IX</b>
<b>THESIS DECLARATION</b> .....	<b>XII</b>
<b>ACKNOWLEDGEMENTS</b> .....	<b>XIII</b>
<b>PUBLICATIONS AND COMMUNICATION TO LEARNED SOCIETIES</b> .....	<b>XIV</b>
<b>PRIZES AND AWARDS DURING CANDIDATURE</b> .....	<b>XVI</b>
<b>CHAPTER ONE</b> .....	<b>1</b>
<b>LITERATURE REVIEW</b> .....	<b>1</b>
<b>1.1. INTRODUCTION</b> .....	<b>1</b>
1.1.1. <i>Incidence and Prevalence of Atrial Fibrillation</i> .....	2
<b>1.2. RISK FACTORS FOR ATRIAL FIBRILLATION</b> .....	<b>4</b>
1.2.1. <i>Major Risk Factors for Atrial Fibrillation</i> .....	4
1.2.2. <i>Novel Risk Factors for AF</i> .....	7
<b>1.3. MECHANISMS OF AF</b> .....	<b>11</b>
1.3.1. <i>Rapid Ectopic Activity</i> .....	11
1.3.2. <i>Single and Multiple Circuit Re-entry</i> .....	13
1.3.3. <i>Endocardial-epicardial Wave Breakthrough</i> .....	14
1.3.4. <i>Summary</i> .....	15
<b>1.4. ATRIAL REMODELLING IN AF</b> .....	<b>17</b>
1.4.1. <i>Atrial Tachycardia-induced Remodelling: “AF begets AF”</i> .....	17
1.4.2. <i>Atrial Structural Remodelling: “Atrial Remodelling of a Different Sort”</i> .....	23
1.4.3. <i>Summary</i> .....	27
<b>1.5. CARDIAC AUTONOMIC NERVOUS SYSTEM AND ATRIAL FIBRILLATION</b> .....	<b>28</b>
1.5.1. <i>Physiology of Heart Rate Variability</i> .....	28
1.5.2. <i>Vagal Contributions to Heart Rate Variability</i> .....	29
1.5.3. <i>Sympathetic Contributions to Heart Rate Variability</i> .....	30
1.5.4. <i>Heart Rate Variability and Atrial Fibrillation</i> .....	30
1.5.5. <i>Summary</i> .....	32
<b>1.6. METABOLIC SYNDROME, OBESITY, DIABETES AND ITS ROLE IN AF DEVELOPMENT</b> .....	<b>34</b>
1.6.1. <i>Metabolic Syndrome</i> .....	34
1.6.2. <i>Association of Obesity to AF development</i> .....	35
1.6.3. <i>Atrial Remodelling in Obesity</i> .....	36
1.6.4. <i>Association of Diabetes with AF development</i> .....	38
1.6.5. <i>Atrial Remodelling in Diabetes</i> .....	39
<b>1.7. HYPERTROPHIC CARDIOMYOPATHY AS A CAUSE FOR AF</b> .....	<b>42</b>
1.7.1. <i>Hypertrophic Cardiomyopathy and its association with AF development</i> .....	42
1.7.2. <i>Atrial Remodelling in Hypertrophic Cardiomyopathy</i> .....	44

1.8. SUMMARY AND DIRECTIONS .....	47
<b>CHAPTER TWO .....</b>	<b>53</b>
<b>ELECTROPHYSIOLOGICAL AND STRUCTURAL REMODELLING OF THE ATRIA IN HYPERTROPHIC CARDIOMYOPATHY: IMPLICATIONS FOR ATRIAL FIBRILLATION .....</b>	<b>53</b>
2.1. INTRODUCTION .....	53
2.2. METHODS.....	56
2.2.1. <i>Animal Model</i> .....	56
2.2.2. <i>Heart Rate and Blood Pressure</i> .....	56
2.2.3. <i>Electrophysiology Study (Multi-Electrode Array)</i> .....	57
2.2.4. <i>Atrial Refractoriness</i> .....	58
2.2.5. <i>Conduction Analysis</i> .....	58
2.2.6. <i>Intracellular Action Potential Recording</i> .....	59
2.2.7. <i>Structural Analysis</i> .....	60
2.2.8. <i>Multiplex Enzyme-linked Immunoassay</i> .....	60
2.2.9. <i>Statistical Analysis</i> .....	61
2.3. RESULTS .....	62
2.3.1. <i>Animal Characteristics</i> .....	62
2.3.2. <i>Atrial Action Potential Duration and Effective Refractory Period</i> .....	62
2.3.3. <i>Atrial Conduction</i> .....	63
2.3.4. <i>Arrhythmia Induction</i> .....	64
2.3.5. <i>Atrial Structural Remodelling</i> .....	64
2.3.6. <i>Extracellular Matrix Remodelling</i> .....	64
2.3.7. <i>Changes in Cellular Adhesion and Inflammation</i> .....	65
2.4. DISCUSSION.....	66
2.4.1. <i>Substrate predisposing to AF</i> .....	67
2.4.2. <i>Atrial Remodelling in HCM</i> .....	68
2.4.3. <i>Clinical Implications for AF</i> .....	71
2.4.4. <i>Study Limitations</i> .....	72
2.5. CONCLUSIONS .....	74
<b>TABLE 1. ANIMAL CHARACTERISTICS AND PATHOLOGY ASSESSMENT .....</b>	<b>75</b>
<b>FIGURE LEGENDS .....</b>	<b>76</b>
<b>FIGURE 1.....</b>	<b>79</b>
<b>FIGURE 2.....</b>	<b>80</b>
<b>FIGURE 3.....</b>	<b>81</b>
<b>FIGURE 4.....</b>	<b>82</b>
<b>FIGURE 5.....</b>	<b>83</b>
<b>FIGURE 6.....</b>	<b>84</b>

FIGURE 7.....	85
FIGURE 8.....	86
<b>CHAPTER THREE .....</b>	<b>91</b>
<b>SLOWED ATRIAL AND ATRIOVENTRICULAR CONDUCTION AND DEPRESSED HRV IN A MURINE MODEL OF HYPERTROPHIC CARDIOMYOPATHY .....</b>	<b>91</b>
<b>3.1. INTRODUCTION .....</b>	<b>91</b>
<b>3.2. METHODS.....</b>	<b>94</b>
3.2.1. <i>Animals.....</i>	94
3.2.2. <i>Data Processing and Analyses .....</i>	94
3.2.3. <i>Statistical Analysis.....</i>	95
<b>3.3. RESULTS .....</b>	<b>96</b>
3.3.1. <i>Study Design.....</i>	96
3.3.2. <i>ECG Parameters .....</i>	96
3.3.3. <i>HRV Parameters.....</i>	96
<b>3.4. DISCUSSION.....</b>	<b>98</b>
3.4.1. <i>Study Limitations.....</i>	101
3.4.2. <i>Conclusions.....</i>	101
<b>TABLE 1. COMPARISON OF ECG PARAMETERS BETWEEN CONTROL AND TG MICE AT 30 AND 50 WEEKS OF AGE .....</b>	<b>103</b>
<b>TABLE 2. COMPARISON OF HRV PARAMETERS BETWEEN CONTROL AND TG MICE AT 30 AND 50 WEEKS OF AGE .....</b>	<b>104</b>
<b>FIGURE LEGENDS .....</b>	<b>105</b>
<b>FIGURE 1.....</b>	<b>106</b>
<b>FIGURE 2.....</b>	<b>107</b>
<b>CHAPTER FOUR .....</b>	<b>112</b>
<b>ATRIAL ELECTROPHYSIOLOGICAL AND STRUCTURAL REMODELLING IN DIABESITY: IMPLICATIONS FOR ARRHYTHMOGENESIS IN DIET-INDUCED OBESITY IN A MURINE MODEL OF TYPE II DIABETES.....</b>	<b>112</b>
<b>4.1. INTRODUCTION .....</b>	<b>112</b>
<b>4.2. METHODS.....</b>	<b>115</b>
4.2.1. <i>Animal Models .....</i>	115
4.2.2. <i>Blood and Urine Glucose levels .....</i>	116
4.2.3. <i>Electrophysiology Study .....</i>	116

4.2.4.	<i>Intracellular Action Potential Recording</i> .....	117
4.2.5.	<i>Atrial Refractoriness</i> .....	118
4.2.6.	<i>Conduction Analysis</i> .....	118
4.2.7.	<i>Structural Analysis</i> .....	119
4.2.8.	<i>Slide-based Multiplex ELISA</i> .....	119
4.2.9.	<i>Statistical Analysis</i> .....	120
<b>4.3.</b>	<b>RESULTS</b> .....	<b>121</b>
4.3.1.	<i>Animal Characteristics</i> .....	121
4.3.2.	<i>Atrial Effective Refractory Period and Action Potential Duration in Diabetes</i> .....	122
4.3.3.	<i>Slowed and Heterogeneous Atrial Conduction in Diabetes</i> .....	123
4.3.4.	<i>Arrhythmia Inducibility in Diabetes Mice</i> .....	125
4.3.5.	<i>Atrial Histopathology in Diabetes</i> .....	125
4.3.6.	<i>Biomarkers of Extracellular Matrix Remodelling</i> .....	127
4.3.7.	<i>Biomarkers of Inflammation/Leukocyte and Monocyte Activation</i> .....	128
<b>4.4.</b>	<b>DISCUSSION</b> .....	<b>129</b>
4.4.1.	<i>Electrophysiology of the Diabetes Atria</i> .....	131
4.4.2.	<i>Histopathology of the Diabetes Atria</i> .....	132
4.4.3.	<i>Biomarkers of Extracellular Matrix Remodelling and Inflammation in Diabetes</i> 133	
4.4.4.	<i>Clinical Implications for AF</i> .....	135
4.4.5.	<i>Study Limitations</i> .....	136
<b>4.5.</b>	<b>CONCLUSIONS</b> .....	<b>137</b>
	<b>TABLE 1. ANIMAL CHARACTERISTICS</b> .....	<b>138</b>
	<b>FIGURE LEGENDS</b> .....	<b>139</b>
	<b>FIGURE 1</b> .....	<b>143</b>
	<b>FIGURE 2</b> .....	<b>144</b>
	<b>FIGURE 3</b> .....	<b>145</b>
	<b>FIGURE 4</b> .....	<b>146</b>
	<b>FIGURE 5</b> .....	<b>147</b>
	<b>FIGURE 6</b> .....	<b>148</b>
	<b>FIGURE 7</b> .....	<b>149</b>
	<b>FIGURE 8</b> .....	<b>150</b>
	<b>FIGURE 9</b> .....	<b>151</b>
	<b>FIGURE 10</b> .....	<b>152</b>
	<b>CHAPTER FIVE</b> .....	<b>157</b>

<b>DEPRESSED HRV AND SLOWED ATRIAL AND ATRIOVENTRICULAR CONDUCTION IN DIABESITY: A POLYGENIC MOUSE MODEL OF DIABETES AND OBESITY .....</b>	<b>157</b>
<b>5.1. INTRODUCTION .....</b>	<b>157</b>
<b>5.2. METHODS.....</b>	<b>161</b>
5.2.1. <i>Mouse Models.....</i>	161
5.2.1. <i>Mouse Electrocardiography.....</i>	161
5.2.2. <i>Data Processing and Analyses .....</i>	162
5.2.3. <i>Statistical Analysis.....</i>	163
<b>5.3. RESULTS .....</b>	<b>164</b>
5.3.1. <i>Animal Characteristics .....</i>	164
5.3.2. <i>ECG parameters .....</i>	164
5.3.3. <i>HRV parameters.....</i>	165
5.3.4. <i>Association of P-wave and RMSSD to Obesity and Hyperglycaemia.....</i>	166
<b>5.4. DISCUSSION.....</b>	<b>168</b>
5.4.1. <i>Clinical Implications .....</i>	171
5.4.2. <i>Study Limitations.....</i>	171
<b>5.5. CONCLUSIONS .....</b>	<b>173</b>
<b>FIGURE LEGENDS .....</b>	<b>174</b>
<b>FIGURE 1.....</b>	<b>178</b>
<b>FIGURE 2.....</b>	<b>179</b>
<b>FIGURE 3.....</b>	<b>180</b>
<b>FIGURE 4.....</b>	<b>181</b>
<b>FIGURE 5.....</b>	<b>182</b>
<b>FIGURE 6.....</b>	<b>183</b>
<b>FIGURE 7.....</b>	<b>184</b>
<b>FIGURE 8.....</b>	<b>185</b>
<b>CHAPTER SIX .....</b>	<b>186</b>
<b>FINAL DISCUSSIONS .....</b>	<b>186</b>
<b>6.1. ATRIAL REMODELLING IN HYPERTROPHIC CARDIOMYOPATHY: IMPLICATIONS FOR ATRIAL FIBRILLATION .....</b>	<b>186</b>
6.1.1. <i>Atrial electrophysiological and structural remodelling in the TnI-203 HCM mouse</i>	188
6.1.2. <i>Biomarkers of extracellular matrix remodelling and inflammation in HCM...</i>	192

<b>6.2. SLOWED ATRIAL AND ATRIOVENTRICULAR CONDUCTION IN HYPERTROPHIC CARDIOMYOPATHY: BASED ON ELECTROCARDIOGRAM PARAMETERS IN THE TNI-203 MOUSE.....</b>	<b>195</b>
<b>6.3. AUTONOMIC NEUROPATHY IN HYPERTROPHIC CARDIOMYOPATHY: EVIDENCE FROM HEART RATE VARIABILITY STUDIES IN TNI-203 MICE .....</b>	<b>197</b>
<b>6.4. ATRIAL REMODELLING IN DIABESITY: IMPLICATIONS FOR ATRIAL FIBRILLATION .....</b>	<b>200</b>
6.4.1. <i>Diet-induced Obesity, Hyperglycaemia, Leptin, and Adiponectin Alterations in RCS10 Mice.....</i>	202
6.4.2. <i>Atrial Electrophysiological Remodelling and Structural Remodelling in diabetes 202</i>	
6.4.3. <i>Alterations in Biomarkers of Extracellular Remodelling and Inflammation ...</i>	204
<b>6.5. SLOWED ATRIAL AND ATRIOVENTRICULAR CONDUCTION IN DIABESITY: BASED ON ELECTROCARDIOGRAM PARAMETERS IN THE NONCNZO10/LTJ MOUSE.....</b>	<b>206</b>
<b>6.6. HEART RATE VARIABILITY AS A MEASURE OF CARDIAC AUTONOMIC NEUROPATHY IN DIABESITY.....</b>	<b>209</b>
<b>TABLE 1. CURRENT LITERATURE ON HEART RATE VARIABILITY IN RODENT MODELS OF TYPE 2 DIABETES AND DIET-INDUCED OBESITY. ....</b>	<b>212</b>
<b>CHAPTER SEVEN.....</b>	<b>213</b>
<b>FUTURE DIRECTIONS .....</b>	<b>213</b>
<b>7.1. INTRINSIC VS. SECONDARY ATRIAL MYOPATHY IN HYPERTROPHIC CARDIOMYOPATHY? .....</b>	<b>213</b>
<b>7.2. REVERSE ATRIAL REMODELLING: TARGETING INFLAMMATION, OXIDATIVE STRESS, AND ATTENUATING FIBROSIS .....</b>	<b>216</b>
<b>7.3. LIFESTYLE MODIFICATIONS AND PHARMACOTHERAPIES TO REVERSE ATRIAL REMODELLING IN HYPERTROPHIC AND DIABESITY-INDUCED CARDIOMYOPATHY: ROLE OF INFLAMMATION, OXIDATIVE STRESS, AND FIBROSIS.....</b>	<b>218</b>
7.3.1. <i>Lifestyle Changes Through Physical Activity and Diet Modifications.....</i>	218
7.3.2. <i>Pharmacotherapies Targeting Inflammation, Oxidative Stress and Fibrosis..</i>	220
<b>REFERENCES.....</b>	<b>224</b>



## **ABSTRACT**

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and contributes to significant morbidity and mortality risks in patients. Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiac disorder and whilst ventricular cardiomyopathy has been well characterised, the atrial substrate contributing to AF has not.

**Chapter 2** assessed the underlying atrial electrophysiological, structural and biomarkers alterations in transgenic mice with a monogenic mutation in Troponin-I as a model of HCM. Also described are the changes in the atrial substrate with chronicity of HCM (30 vs. 50 weeks of age). Mice with established HCM (30 weeks) demonstrate increased bi-atrial mass associated with atrial myocyte hypertrophy, increased fibrosis and inflammatory cell infiltration. Electrophysiological parameters demonstrate decreased action potential durations, normal refractoriness, normal but heterogeneous conduction in the HCM atria. Conversely, biomarkers of extracellular matrix remodelling and inflammation were not altered in 30-week old HCM mice. With older age, HCM mice demonstrate progressively increased refractoriness and slowed conduction, as well as changes in biomarkers for extracellular matrix remodelling and inflammation.

**Chapter 3** characterizes electrocardiography (ECG) changes that are indicative of conduction time within compartments of the heart and HRV as a measure of cardiac autonomic function in HCM mice. HCM mice demonstrated slowed atrial and atrioventricular conduction (as measured by P wave duration

and PR intervals respectively), as well as depressed HRV (as shown by decreased standard deviation of RR intervals (SDRR), coefficient of variation of RR intervals (CVRR), and standard deviation of heart rate (SDHR)). No significant age-related difference was observed in all ECG and HRV parameters.

Although diabetes and obesity (collectively termed as diabetes) are increasingly prevalent in humans and independently associated with AF development; the atrial substrate accounting for AF has not been fully understood. Animal models used in diabetes research are often of monogenic aetiology that demonstrates severe clinical phenotypes uncharacteristic of humans. Studies in polygenic models that better represent human diabetes are warranted.

**Chapter 4** describes electrophysiological and structural changes in the atria of young (10-week old) and matured (30-week old) polygenic NONcNZO10/LtJ (RCS10) mice prone to diabetes development with high fat diet and/or increasing age. Young RCS10 mice with diet-induced progressive obesity and hyperglycaemia demonstrated increased refractoriness and action potential durations, slowed and heterogeneous conduction, increased myocyte hypertrophy, fibrosis and inflammatory cell infiltration in the atria. Matured RCS10 mice demonstrated similar electrophysiological and structural substrates with the exception of unchanged atrial refractoriness and action potential durations. Furthermore, biomarkers of extracellular matrix remodelling and inflammation in this model were altered.

**Chapter 5** examines ECG and HRV modulations in the RCS10 mice with age and diet-induced diabetes. RCS10 mice demonstrated atrial and atrioventricular conduction delay (as evident by increased PR intervals and progressively prolonged P wave durations respectively). RCS10 mice also demonstrated reduced SDRR and RMSSD indicative of reduced HRV. Age was not a significant contributor of ECG and HRV changes. Increased severity of obesity and diabetes had a minor but significant correlation to worse P wave duration and depressed RMSSD.

## **THESIS DECLARATION**

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Wei Wen Lim  
DECEMBER 2015

## **ACKNOWLEDGEMENTS**

I would like to thank Professor Prashanthan Sanders, my primary supervisor, for his mentorship and support during the course of my studies. I am particularly encouraged for his clinical insights, originality of ideas, and driven attitude to accomplish and lead multiple projects to completion. I would like to thank Professor David Saint, my secondary supervisor, for his continued support and wealth of knowledge that has helped me through my projects and writing. I am also thankful to my co-supervisors, Dr Pawel Kuklik, Dr Anand Ganesan, Dr Mathias Baumert, Professor Christopher Semsarian, for their guidance throughout the course of my study. I am grateful to the University of Adelaide for the scholarship support (Adelaide Graduate Research Scholarship).

I am thankful to Professor Christopher Semsarian for his provision of the Gly203Ser cardiac Troponin-I mutant mice and Dr Elizabeth Beckett for providing me with the NONcNZO10/LtJ and SWR/J mice colonies to perform my studies. I am indebted to the staff of the Laboratory Animal Services (especially Pacita Wissell, Alice Parmiter, & Xavier Curlija) for their support and assistance in maintaining the mice breeding colonies without which these studies would not be possible.

I am blessed by the unwavering support of my beloved partner, Melissa Neo who has supported me throughout the course of my study sharing my tribulations and joys. I am also blessed to have the emotional support and financial assistance from my parents whom have understood and given their full support in my pursuit for higher education. Lastly, I thank our God for His unreserved favour, love and blessings for me.

## **PUBLICATIONS AND COMMUNICATION TO LEARNED**

### **SOCIETIES**

#### **Chapter 2**

1. **Manuscript:** Lim WW, Neo M, Thanigaimani S, Kuklik P, Ganesan AN, Baumert M, Lau DH, Tsoutsman T, Kalman JM, Semsarian C, Saint DA, Sanders P. Atrial Electrophysiological and Structural Remodelling in Hypertrophic Cardiomyopathy in a Murine Model of Troponin-I Mutations: Implications for Atrial Fibrillation (prepared in publication format)
2. **Presentation:** Presented at the Australian Physiological Society November 2014, Brisbane, Australia
3. **Presentation:** Presented at the Florey Postgraduate Research Conference September 2014, Adelaide, Australia

#### **Chapter 3**

1. **Manuscript:** Lim WW, Baumert M, Neo M, Kuklik P, Ganesan AN, Lau DH, Tsoutsman T, Semsarian C, Sanders P, Saint DA. Slowed Atrial and Atrioventricular Conduction and Depressed HRV in a Murine Model of Hypertrophic Cardiomyopathy. *Clinical and Experimental Pharmacology and Physiology* (accepted manuscript)
2. **Presentation:** Presented at the Australian Physiological Society November 2014, Brisbane, Australia
3. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand August 2015, Melbourne, Australia

## Chapter 4

1. **Manuscript:** Lim WW, Neo M, Kuklik P, Ganesan AN, Baumert M, Lau DH, Kalman JM, Semsarian C, Saint DA, Sanders P. Atrial Electrophysiological and Structural Remodelling in Diabesity: Implications for Arrhythmogenesis in Diet-induced Obesity in a Murine Model of Type II Diabetes. (prepared in publication format)
2. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand August 2015, Melbourne, Australia and published in abstract form (*Heart, Lung and Circulation* 22 (2013): S94)
3. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand August 2015, Melbourne, Australia and published in abstract form (*Heart, Lung and Circulation* 22 (2013): S96)
4. **Presentation:** Presented at the Cardiac Society of Australia and New Zealand August 2015, Melbourne, Australia and published in abstract form (*Heart, Lung and Circulation* 21 (2012): S100)

## Chapter 5

1. **Manuscript:** Lim WW, Neo M, Kuklik P, Ganesan AN, Baumert M, Lau DH, Kalman JM, Semsarian C, Saint DA, Sanders P. Depressed HRV and Slowed Atrial and Atrioventricular Conduction in Diabesity: A Polygenic Mouse Model of Diabetes and Obesity (prepared in publication format)

## **PRIZES AND AWARDS DURING CANDIDATURE**

1. Adelaide Graduate Research Scholarship (2011-2014)
2. Australian Physiological Society Student Travel Claim for AUPS 2014
3. International Society for Heart Research Travel Bursary for CSANZ 2015